Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

PolandBack to Poland

Clinical trials in Lodz – page 44

1 013 clinical trials in Lodz, Poland across 17 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

PolandOur site in PolandBadaniaKliniczne.pl(opens in a new tab)
Lodz at a glance
1 013
clinical trials
  • Research sites17
Type of trial
Recruitment status
Quick filters

1 013 trials in Lodz

Open in trial search

Colitis ulcerative+1

Not recruiting

Study on the Long-Term Effects of TEV-48574 (Duvakitug) for Adults with Moderate to Severe Ulcerative Colitis or Crohn's Disease

InvestigationalNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Duvakitug
  • Sponsor:Teva Branded Pharmaceutical Products R&D LLC

Osteoporosis

Not recruiting

Study Comparing MAB-22 and Denosumab for Treating Osteoporosis in Postmenopausal Women

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Denosumab
  • Sponsor:Xentria Inc.

Systemic scleroderma

Not recruiting

Study on the Effects of Fipaxalparant in Patients with Diffuse Cutaneous Systemic Sclerosis

InvestigationalNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Fipaxalparant
  • Sponsor:Horizon Therapeutics Ireland Designated Activity Company

Hot flush

Not recruiting

Study of Fezolinetant for Hot Flashes in Women with Hormone Receptor-Positive Breast Cancer Receiving Hormone Therapy

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Fezolinetant
  • Sponsor:Astellas Pharma Global Development Inc.

Colitis ulcerative

Not recruiting

Study of Tulisokibart for Patients with Moderately to Severely Active Ulcerative Colitis

InvestigationalNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Tulisokibart
  • Sponsor:Prometheus Biosciences Inc.

Ovarian cancer

Not recruiting

Study on the Effectiveness of Durvalumab, Olaparib, and Bevacizumab in Patients with Newly Diagnosed Advanced Ovarian Cancer

Registered drug
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:AstraZeneca AB

Acute lymphocytic leukaemia

Not recruiting

Study on Obinutuzumab and Rituximab with Chemotherapy for Adults with Newly Diagnosed CD20-Positive Acute Lymphoblastic Leukemia

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Obinutuzumab
  • Sponsor:Narodowy Instytut Onkologii Im. Marii Sklodowskiej-Curie-Panstwowy Instytut Badawczy

Hypertriglyceridaemia

Not recruiting

Study to Evaluate Plozasiran for Adults with High Triglycerides

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Synthetic Double-Stranded Sirna Oligonucleotide Directed Against Apolipoprotein C-Iii Mrna And Covalently Linked To A Ligand Containing Three N-Acetylgalactosamine Residues
  • Sponsor:Arrowhead Pharmaceuticals Inc.

Idiopathic generalised epilepsy

Not recruiting

Study on BHV-7000 for Patients with Generalized Tonic-clonic Seizures in Idiopathic Generalized Epilepsy

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Bhv-7000
  • Sponsor:Biohaven Therapeutics Ltd.

Systemic lupus erythematosus

Not recruiting

Study of Obexelimab Treatment for Adults with Systemic Lupus Erythematosus (SLE)

Registered drug
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Obexelimab
  • Sponsor:Zenas Biopharma (USA) LLC

Diffuse large B-cell lymphoma

Not recruiting

Study on the Effectiveness and Safety of Polatuzumab Vedotin, Rituximab, and CHP in Patients with Untreated Diffuse Large B-Cell Lymphoma

Registered drug
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Polatuzumab Vedotin
  • Sponsor:F. Hoffmann-La Roche AG

Chronic spontaneous urticaria

Not recruiting

Study on Barzolvolimab for Patients with Chronic Spontaneous Urticaria Unresponsive to H1 Antihistamines

Registered drug
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Barzolvolimab
  • Sponsor:Celldex Therapeutics Inc.

Other cities in Poland

The busiest research cities in the country

All 239 cities in Poland

Clinical research in Lodz

What the registry says about research in the country

01 Respiratory Research

Ongoing clinical trials focusing on respiratory viral infections and preventive vaccines, particularly targeting RSV and influenza in older adults. Studies evaluate vaccine efficacy and immune responses to protect against severe respiratory diseases.

  • RSV and Influenza Prevention
  • Vaccine Immunogenicity
  • COPD Management

Multiple studies assess combination vaccines and co-administration strategies to enhance protection against multiple respiratory pathogens.

02 Dermatological Studies

Innovative research examining treatments for plaque psoriasis and related conditions. Trials investigate novel therapeutic approaches including oral medications and biological treatments for moderate to severe cases.

  • Psoriasis Treatment
  • Hidradenitis Suppurativa
  • Inflammatory Skin Conditions

Studies focus on measuring improvement in disease severity and quality of life outcomes for patients.

03 Immunology and Vaccines

Comprehensive research on meningococcal and pneumococcal vaccines, with special attention to pediatric populations. Studies evaluate safety profiles and immune responses across different age groups.

  • Pediatric Vaccinations
  • Immune Response Assessment
  • Preventive Medicine

Trials incorporate multiple age cohorts from infants to adolescents, ensuring comprehensive vaccine effectiveness data.

Back to PolandAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.